GlassScriptPhysician profile
Kim M Rice
NPI 1184695025
$2,123.18
in general payments reported to CMS, 2019-2025
32 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $173 · 2021: $104 · 2022: $99.03 · 2023: $501 · 2024: $737 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,602 · Education: $0.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,602.32 |
| Education | $0.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $412.69 | 2023-2025 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $320.93 | 2020-2023 | Krystexxa |
| Nxstage Medical, INC. | $147.85 | 2024 | |
| Abbvie INC. | $112.19 | 2020 | |
| Genentech, INC. | $109.91 | 2019 | |
| Merck Sharp & Dohme LLC | $105.69 | 2023-2025 | Prevymis, Dificid |
| Mallinckrodt Hospital Products INC. | $90.39 | 2023-2024 | Acthar |
| Glaxosmithkline, LLC. | $81.11 | 2023-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $80.74 | 2021-2023 | Farxiga |
| Veloxis Pharmaceuticals, INC. | $79.19 | 2021-2024 | Envarsus |
| Eurofins Viracor, LLC | $68.33 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $67.53 | 2019-2025 | Jynarque |
| Novo Nordisk INC | $55.23 | 2021-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.89 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $37.15 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $28.82 | 2025 | Givlaari |
| Takeda Pharmaceuticals U.S.A., INC. | $27.20 | 2022 | |
| Evoke Pharma, INC. | $26.86 | 2020 | |
| Fresenius USA Marketing, INC. | $25.30 | 2023 | Velphoro |
| Kyowa Kirin, INC. | $22.37 | 2025 | |
| Chiesi USA, INC. | $20.56 | 2025 | Elfabrio |
| Travere Therapeutics, INC. | $20.46 | 2023-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $19.04 | 2025 | |
| Akebia Therapeutics INC | $18.60 | 2019 | |
| Amarin Pharma, INC. | $18.29 | 2021 | |
| Opko Pharmaceuticals, LLC | $17.11 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.69 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.43 | 2023 | |
| Calliditas Therapeutics US INC. | $13.71 | 2024 | |
| Idorsia Pharmaceuticals US INC | $13.38 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $12.54 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.